Aether Industries Q1 FY27 Earnings Call Summary

Event Participants

Executives

5
Aman Desai, Faiz Nagariya, Kushal Doshi, Rohan Desai, Shubhangi Desai

Analysts

11
Akshay, Bhavika Singhvi, Chaitanya Kamdar, Divya Kasera, Jaspreet Singh, Keshav Bharadia, Nilesh Ghuge, Pankaj K, Rohit Nagraj, Sajal Kapoor, Soham Jain

Financials & KPIs

Geographic & Segment Commentary

CRAMS & CEM (Contract Models): Now ~50% of revenue and described by management as the company's "backbone." 10 new marquee clients onboarded and more than nine customer/certification audits cleared in Q1 FY27. CEM contracts run at 28-30% EBITDA margins, so the mix shift is margin-accretive; management targets 70%+ revenue contribution within two years, citing rising urgency from European customers where in-house manufacturing economics have deteriorated.

Large Scale Manufacturing (LSM): Volume declined 22.5% YoY due to deliberate reallocation of production lines to CEM contracts; management confirmed no demand decline, with LSM pricing up 22.5%. Despite 30-35% post-COVID Chinese price corrections, management states it has never lost market share on its products and remains competitive; LSM expected to decline to ~35% of total revenue over the next few years.

Oil & Gas: 20% of revenue (₹100 crores) in Q1 FY27, largely Baker Hughes-driven. Baker Hughes has scaled from ~₹45 crores in Q1 FY26 to ~₹70 crores current Site 4 run-rate, with continuous new product launches under exclusive manufacturing partnerships; the dedicated Site 5 facility for this sector continues to scale.

Semiconductor / Electronic Materials (Magnum, Site 5): First three LSM products (pharma, agrochemical, material science) at $30-40/kg entered commercial sales in Q1 with revenue contribution from Q2 FY27; made in India for the first time, positioning as import substitution with export potential. Low-dielectric semiconductor monomers (~$50/kg, 400 TPA capacity growing 3x by 2030) serve silane coupling agents, PPE-type resins and low-dielectric formulations for 5G/AI high-speed PCBs; qualification batches complete and small orders being delivered, with the main 45 TPM stream (3×15 TPM lines) online by end-September 2026.

Silicones (Dow Partnership): Announced July 30, 2026 — an exclusive multi-year collaborative research program with Dow Chemical to develop new manufacturing technologies for silicones, one of India's first programs of its kind. All research and pilot scale-up will occur at Aether's R&D and pilot plant facilities in Surat; the agreement includes a framework for potential commercialization and industrial-scale manufacturing. Foundational silicone molecules are not manufactured in India today and are largely imported; management views this as a platform entry into India's multi-billion-dollar silicones market growing at 7-10% CAGR.

Company-Specific & Strategic Commentary

Dow Chemical Partnership: Exclusive multi-year research program to develop new silicone manufacturing technologies; marks Aether's entry into platform silicones chemistry. Built on deep institutional history — Dr. Aman Desai worked three years in Dow's core R&D, CTO Dr. James Ringer and business development leader Ray Roach each spent 30+ years at Dow. Management expects the program to open the door to broader Dow opportunities over time.

Magnum Site 5 Expansion: Mega site at Panoli with 16 production blocks commissioned in phases; Phase I online with expected asset turn of 1.5-1.75x once fully operational. Total investment of ₹2,200-2,300 crores with Phase II targeted by FY2030; customers have pre-audited the site and demand is lined up ahead of capacity.

R&D Engine Expansion: Interim R&D expansion complete with additional fume hoods and a new 400 MHz NMR in service. A larger facility with ~15 new labs and close to 160 cumulative fume hoods is on track for commissioning in FY2028, enabling more complex chemistry at higher value.

Contract Pipeline Depth: For every publicly announced customer (Baker Hughes, Milliken, Seqens, Saudi Aramco, Dow, Polaroid, Otsuka), management notes four to five additional relationships under NDA at various stages; name disclosures are subject to customer approval. Q1 FY27 saw 10 new marquee client onboardings and more than nine audits cleared.

Insurance Settlement: Final claim for fixed assets lost in the November 2023 fire was received in Q1 FY27, completing the full insurance settlement.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Semiconductor Materials: Orders, Applications & Commercialization

• Question: What orders are in hand for the semiconductor segment, and which chemistries are involved? (Nilesh Ghuge, HDFC Securities)
• Answer: Order book and product names will not be disclosed for competitive reasons; Aether is pursuing a focused basket of high-value molecules emphasizing depth over breadth. The chemistry draws directly on core competencies in process chemistry, coupling agent and monomer stability — the same capabilities as the CRAMS/CEM businesses (Rohan Desai).
• Question: When will commercial supply start? (Akshay, AK Investment)
• Answer: Semiconductor products are already being manufactured at Site 3 — qualification batches completed, samples submitted, and small quantity orders are being delivered. The main stream at Site 5 (Magnum) with 45 TPM capacity split into three 15 TPM lines is targeted online by end-September 2026 (Rohan Desai).
• Question: What are the applications and potential size, and any ISM 2.0 benefit? (Keshav Bharadia, Wallfort Financial Services)
• Answer: Applications sit in the 5G/AI hardware supply chain — building blocks for silane coupling agents that bond glass fiber/resin layers, PPE-type resins for copper-clad laminates, and low-dielectric formulations for high-speed PCBs. Starting capacity is 400 TPA growing 3x by 2030 at ~$50/kg; Aether is applying for ISM 2.0 benefits, though the scheme structure is still being clarified (Rohan Desai).

Magnum Site 5 LSM Products & Pricing

• Question: What is the order book and can you share product or end-user names for the new LSM products from Magnum? (Nilesh Ghuge, HDFC Securities)
• Answer: Commercial sales of the first three new LSM products (pharmaceutical, agrochemical, material science) began in Q1 FY27, with revenue contribution expected from Q2 FY27. Products are priced at $30-40/kg and made in India for the first time — clear import substitution with export potential. The pharma intermediate, which lowers cholesterol/triglyceride levels and prevents heart attacks/strokes, is already being produced at Site 3 at 10-15 TPM to accelerate timelines; product names remain confidential (Rohan Desai).

Dow Collaboration: Scope, Timeline & Exclusivity

• Question: What is being developed under the Dow program, who are the major players, and what should investors track? (Chaitanya Kamdar, Avestha Fund Management; Keshav Bharadia, Wallfort Financial Services)
• Answer: This is a platform technology program developing new manufacturing methods for silicones, not a single product. India imports the majority of its silicones from China, Germany and the US, with no domestic foundational silicone manufacturing. Investors should track: completion of pilot work at Surat, transition into a definitive commercial framework with Dow, and a potential future CapEx commitment on a dedicated block/site (Aman Desai).
• Question: Is the exclusivity limited to India or specific product lines? (Soham Jain, Dalal & Broacha)
• Answer: Exclusivity applies within the research program specifically targeting new ways of manufacturing silicones in India — Dow will only work with Aether and Aether only with Dow for this program (Aman Desai).
• Question: Timeline for meaningful breakthrough and industrial-scale manufacturing? (Keshav Bharadia, Wallfort Financial Services)
• Answer: This is a multi-year research program with no specific timeline disclosed; the objective is to scale and move up the value chain as results mature (Aman Desai).

Dow Partnership: Strategic Upside & Relationship Depth

• Question: What is Aether's economic upside beyond CRAMS revenue from this program? (Chaitanya Kamdar, Avestha Fund Management)
• Answer: The program creates a new platform in silicones chemistry — one of the largest material classes Aether was not previously in — and deepens the silanes/silicones platform adjacent to the semiconductor opportunity. It positions Aether to address India's silicones market, which management termed a multi-billion-dollar opportunity growing at 7-10% CAGR; Dow selecting Aether as exclusive research partner validates its process chemistry and scale-up capabilities (Aman Desai).
• Question: At what point does the Dow relationship become genuinely hard to replace? (Sajal Kapoor, Antifragile Thinking)
• Answer: It is already a genuine multi-year partnership; it becomes inseparable once scale-up and commercialization alignment is achieved. Management cites deep institutional history — Dr. Aman Desai spent three years in Dow's core R&D, and Aether's CTO and business development leader each spent 30+ years at Dow — and expects this first program to open other Dow opportunities (Aman Desai).

CRAMS/CEM Pipeline & Customer Onboarding

• Question: What other European or US majors are in discussions to shift manufacturing to India, and when could announcements come? (Keshav Bharadia, Wallfort Financial Services)
• Answer: For every publicly announced client (Baker Hughes, Milliken, Seqens, Dow, Polaroid, Otsuka), there are four to five others at various stages under NDA whose name disclosures customers have not approved; expect more announcements in the near to mid-term (Aman Desai).
• Question: Have new products been commercialized for Baker Hughes and Milliken? (Bhavika Singhvi, Niveshaay)
• Answer: Yes — new Baker Hughes products have been added since the last call under an exclusive family of products. The Milliken agreement is a multi-year supply deal for one key strategic molecule, with a partnership history spanning 9-10 years (Aman Desai).

Positioning in Semiconductor Value Chain vs Fab-Level Players

• Question: How does Aether's offering differ from other entrants such as Sumitomo Chemical manufacturing semiconductor process chemicals in India? (Soham Jain, Dalal & Broacha)
• Answer: Recent entrants target fab-level consumables — high-purity gases, solvents, photoresists, CMP chemicals — which are largely purification and scale plays requiring heavy CapEx and long fab qualification cycles. Aether's entry point is advanced electronic materials: low-dielectric materials inside high-speed circuit boards for 5G/AI hardware, built from complex, low-volume, high-value specialty monomers — a capital-light, R&D-and-pilot-first approach with a fundamentally different risk profile (Rohan Desai).

LSM Reallocation, China Competition & Oil & Gas Ramp

• Question: Are LSM orders going unserved, and is oil & gas revenue recurring or one-time? (Divya Kasera, Craving Alpha Wealth Fund)
• Answer: The 22.5% LSM volume decline reflects deliberate reallocation of production lines to higher-margin CM contracts; demand remains intact and LSM pricing improved 22.5%. Oil & gas revenue is largely Baker Hughes-driven — scaled from ~₹45 crores in Q1 FY26 to ~₹70 crores current Site 4 run-rate — with other oil & gas customers also being serviced (Faiz Nagariya; Rohan Desai).
• Question: How has strategy changed to avoid Chinese price competition on newer molecules? (Rohit Nagraj, 360 ONE Capital)
• Answer: Focus has shifted to CRAMS and CEM (targeting 70%+ of revenue); in LSM, Aether has never lost market share even when prices corrected 30-35% post-COVID. Recent price corrections are acknowledged, but the company remains competitive across all products it manufactures (Rohan Desai).

Execution Bandwidth & Risk Management

• Question: What could genuinely derail the path given simultaneous segment mix shifts, aggressive capacity expansion, and the Dow partnership? (Pankaj K, Individual Investor)
• Answer: Management remains pragmatic — Magnum was deliberately located in Panoli, the closest chemical zone to Surat, rather than farther sites, and the company is cognizant of core team limitations. Safety is the foremost priority, followed by execution capability; the technical-commercial promoter leadership enables rapid decision-making and a strong appetite for multidimensional opportunities (Aman Desai).

Key Takeaway

Q1 FY27 revenue of ₹326.6 crores (+27% YoY), EBITDA of ₹102.8 crores (+31% YoY) at a 31% margin, and PAT of ₹62.7 crores (+33% YoY) were driven by CRAMS/CEM scale-up — now ~50% of revenue and targeted to exceed 70% within two years — alongside the Baker Hughes ramp to a ~₹70 crore Site 4 run-rate. Strategic focus centers on three vectors: Magnum (Site 5, ₹2,200-2,300 crores investment, 16 blocks) began semiconductor materials sales (400 TPA growing 3x by 2030, main 45 TPM stream online end-September), the exclusive multi-year Dow silicone technology R&D partnership announced July 30, and a deepening contracted pipeline (10 new marquee clients, 9+ audits cleared in Q1). CapEx is guided at ₹300-350 crores for FY27. Watch execution bandwidth across concurrent expansions, working capital normalization, and conversion of the Dow program and semiconductor orders into commercial revenue.